Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent malignant glioma. Patients and Methods: Gefitinib and sirolimus were administered on a continuous daily dosing schedule at dose levels that were escalated in successive cohorts of malignant glioma patients at any recurrence who were stratified based on concurrent use of CYP3A-inducing anticonvulsants [enzyme-inducing antiepileptic drugs, (EIAED)]. Pharmacokinetic and archival tumor biomarker data were also assessed. Results: Thirty-four patients with progressive disease after prior radiation therapy and chemotherapy were enrolled, including 29 (85%) with glioblastoma multiforme and 5 (15%) with anaplastic glioma. The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs. DLTs included mucositis, diarrhea, rash, thrombocytopenia, and hypertriglyceridemia. Gefitinib exposure was not affected by sirolimus administration but was significantly lowered by concurrent EIAED use. Two patients (6%) achieved a partial radiographic response, and 13 patients (38%) achieved stable disease. Conclusion: We show that gefitinib plus sirolimus can be safely coadministered on a continuous, daily dosing schedule, and established the recommended dose level of these agents in combination for future phase 2 clinical trials.

[1]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[3]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Yoshimura,et al.  Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA) , 2005, British Journal of Cancer.

[5]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[6]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[7]  Susan M. Chang,et al.  Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs , 2004, Investigational New Drugs.

[8]  R. McLendon,et al.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. , 2004, The Journal of molecular diagnostics : JMD.

[9]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[11]  A. Friedman,et al.  Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme , 2004, Clinical Cancer Research.

[12]  R. Kerbel,et al.  Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. , 2004, International journal of radiation oncology, biology, physics.

[13]  Chao Zhang,et al.  Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. , 2003, Cancer research.

[14]  Q. She,et al.  Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  W. Mckenna,et al.  Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. , 2003, Cancer research.

[16]  R. Natale.  O-244 Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor , 2003 .

[17]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[18]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[19]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[20]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[22]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[23]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Mills,et al.  Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. , 1998, Cancer research.

[26]  Gordon Mills,et al.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC , 1998, Current Biology.

[27]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[28]  R. McLendon,et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.

[29]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[30]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[31]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[32]  S. Brem,et al.  Immunolocalization of basic fibroblast growth factor to the micro vasculature of human brain tumors , 1992, Cancer.

[33]  T. Roszman,et al.  Proliferative potential of T-cell lymphocytes from gliomas. , 1992, Journal of neurosurgery.

[34]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[35]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[36]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[37]  Robert E. Gentry,et al.  Immunobiology of primary intracranial tumors. , 1977, Journal of neurosurgery.

[38]  D. Bigner,et al.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. , 1977, Journal of neurosurgery.

[39]  D. Kuypers.  Benefit-Risk Assessment of Sirolimus in Renal Transplantation , 2005, Drug safety.

[40]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[43]  J. Klein,et al.  Small sample moments of some estimators of the variance of the Kaplan−Meier and Nelson-Aalen estimators , 1991 .